SrasV1, PascalFrancis, Curation, bibRecord, 000638

Severe acute respiratory syndrome coronavirus entry as a target of antiviral therapies

Identifieur interne : 000638 ( PascalFrancis/Curation ); précédent : 000637; suivant : 000639

Severe acute respiratory syndrome coronavirus entry as a target of antiviral therapies

Auteurs : Jens H. Kuhn [États-Unis, Allemagne] ; WENHUI LI [États-Unis] ; Sheli R. Radoshitzky [États-Unis] ; Hyeryun Choe [États-Unis] ; Michael Farzan [États-Unis]

Source :

Antiviral therapy : (London) [ 1359-6535 ] ; 2007.

RBID : Pascal:07-0427335

Descripteurs français

Pascal (Inist)
- Syndrome respiratoire aigu sévère, Coronavirus, Traitement, Antiviral, Thérapeutique ciblée.

English descriptors

KwdEn :
- Antiviral, Coronavirus, Severe acute respiratory syndrome, Targeted therapy, Treatment.

Abstract

The identification in 2003 of a coronavirus as the aetiological agent of severe acute respiratory syndrome (SARS) intensified efforts to understand the biology of coronaviruses in general and SARS coronavirus (SARS-CoV) in particular. Rapid progress was made in describing the SARS-CoV genome, evolution and lifecycle. Identification of angiotensin-converting enzyme 2 (ACE2) as an obligate cellular receptor for SARS-CoV contributed to understanding of the SARS-CoV entry process, and helped to characterize two targets of antiviral therapeutics: the SARS-CoV spike protein and ACE2. Here we describe the role of these proteins in SARS-CoV replication and potential therapeutic strategies aimed at preventing entry of SARS-CoV into target cells.

A01	`01`	`1`		`@0 1359-6535`
A03		`1`		`@0 Antivir. ther. : (Lond.)`
A05				`@2 12`
A06				`@2 4 @3 p. b`
A08	`01`	`1`	`ENG`	`@1 Severe acute respiratory syndrome coronavirus entry as a target of antiviral therapies`
A09	`01`	`1`	`ENG`	`@1 Spotlight on respiratory viruses`
A11	`01`	`1`		`@1 KUHN (Jens H.)`
A11	`02`	`1`		`@1 WENHUI LI`
A11	`03`	`1`		`@1 RADOSHITZKY (Sheli R.)`
A11	`04`	`1`		`@1 CHOE (Hyeryun)`
A11	`05`	`1`		`@1 FARZAN (Michael)`
A12	`01`	`1`		`@1 DE JONG (Menno D.) @9 ed.`
A12	`02`	`1`		`@1 HAYDEN (Frederick G.) @9 ed.`
A14	`01`			`@1 Department of Microbiology and Molecular Genetics, Harvard Medical School, New England Primate Research Center @2 Southborough, MA @3 USA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 5 aut.`
A14	`02`			`@1 Department of Biology, Chemistry, Pharmacy, Freie Universität Berlin @2 Berlin @3 DEU @Z 1 aut.`
A14	`03`			`@1 Department of Pediatrics, Children's Hospital, Harvard Medical School @2 Boston, MA @3 USA @Z 4 aut.`
A15	`01`			`@1 Oxford University Clinical Research Unit, Hospital for Tropical Diseases @2 Ho Chi Minh City @3 VNM @Z 1 aut.`
A15	`02`			`@1 University of Virginia School of Medicine @2 Charlotesville, VA @3 USA @Z 2 aut.`
A15	`03`			`@1 Global Influenza Program, World Health Organization @2 Geneva @3 CHE @Z 2 aut.`
A20				`@1 639-650`
A21				`@1 2007`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 27047 @5 354000161541800060`
A44				`@0 0000 @1 © 2007 INIST-CNRS. All rights reserved.`
A45				`@0 163 ref.`
A47	`01`	`1`		`@0 07-0427335`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Antiviral therapy : (London)`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 The identification in 2003 of a coronavirus as the aetiological agent of severe acute respiratory syndrome (SARS) intensified efforts to understand the biology of coronaviruses in general and SARS coronavirus (SARS-CoV) in particular. Rapid progress was made in describing the SARS-CoV genome, evolution and lifecycle. Identification of angiotensin-converting enzyme 2 (ACE2) as an obligate cellular receptor for SARS-CoV contributed to understanding of the SARS-CoV entry process, and helped to characterize two targets of antiviral therapeutics: the SARS-CoV spike protein and ACE2. Here we describe the role of these proteins in SARS-CoV replication and potential therapeutic strategies aimed at preventing entry of SARS-CoV into target cells.
C02	`01`	`X`		`@0 002B02S05`
C02	`02`	`X`		`@0 002B05C02C`
C03	`01`	`X`	`FRE`	`@0 Syndrome respiratoire aigu sévère @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Severe acute respiratory syndrome @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Síndrome respiratorio agudo severo @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Coronavirus @2 NW @5 02`
C03	`02`	`X`	`ENG`	`@0 Coronavirus @2 NW @5 02`
C03	`02`	`X`	`SPA`	`@0 Coronavirus @2 NW @5 02`
C03	`03`	`X`	`FRE`	`@0 Traitement @5 03`
C03	`03`	`X`	`ENG`	`@0 Treatment @5 03`
C03	`03`	`X`	`SPA`	`@0 Tratamiento @5 03`
C03	`04`	`X`	`FRE`	`@0 Antiviral @5 04`
C03	`04`	`X`	`ENG`	`@0 Antiviral @5 04`
C03	`04`	`X`	`SPA`	`@0 Antiviral @5 04`
C03	`05`	`X`	`FRE`	`@0 Thérapeutique ciblée @4 CD @5 96`
C03	`05`	`X`	`ENG`	`@0 Targeted therapy @4 CD @5 96`
C03	`05`	`X`	`SPA`	`@0 Terapéutica dirigida @4 CD @5 96`
C07	`01`	`X`	`FRE`	`@0 Virose`
C07	`01`	`X`	`ENG`	`@0 Viral disease`
C07	`01`	`X`	`SPA`	`@0 Virosis`
C07	`02`	`X`	`FRE`	`@0 Infection`
C07	`02`	`X`	`ENG`	`@0 Infection`
C07	`02`	`X`	`SPA`	`@0 Infección`
C07	`03`	`X`	`FRE`	`@0 Coronaviridae @2 NW`
C07	`03`	`X`	`ENG`	`@0 Coronaviridae @2 NW`
C07	`03`	`X`	`SPA`	`@0 Coronaviridae @2 NW`
C07	`04`	`X`	`FRE`	`@0 Nidovirales @2 NW`
C07	`04`	`X`	`ENG`	`@0 Nidovirales @2 NW`
C07	`04`	`X`	`SPA`	`@0 Nidovirales @2 NW`
C07	`05`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`05`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`05`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`06`	`X`	`FRE`	`@0 Appareil respiratoire pathologie @5 37`
C07	`06`	`X`	`ENG`	`@0 Respiratory disease @5 37`
C07	`06`	`X`	`SPA`	`@0 Aparato respiratorio patología @5 37`
C07	`07`	`X`	`FRE`	`@0 Poumon pathologie @5 38`
C07	`07`	`X`	`ENG`	`@0 Lung disease @5 38`
C07	`07`	`X`	`SPA`	`@0 Pulmón patología @5 38`
N21				`@1 281`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000351

Links to Exploration step

Pascal:07-0427335

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Severe acute respiratory syndrome coronavirus entry as a target of antiviral therapies</title>
<author><name sortKey="Kuhn, Jens H" sort="Kuhn, Jens H" uniqKey="Kuhn J" first="Jens H." last="Kuhn">Jens H. Kuhn</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology and Molecular Genetics, Harvard Medical School, New England Primate Research Center</s1>
<s2>Southborough, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Biology, Chemistry, Pharmacy, Freie Universität Berlin</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Wenhui Li" sort="Wenhui Li" uniqKey="Wenhui Li" last="Wenhui Li">WENHUI LI</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology and Molecular Genetics, Harvard Medical School, New England Primate Research Center</s1>
<s2>Southborough, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Radoshitzky, Sheli R" sort="Radoshitzky, Sheli R" uniqKey="Radoshitzky S" first="Sheli R." last="Radoshitzky">Sheli R. Radoshitzky</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology and Molecular Genetics, Harvard Medical School, New England Primate Research Center</s1>
<s2>Southborough, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Choe, Hyeryun" sort="Choe, Hyeryun" uniqKey="Choe H" first="Hyeryun" last="Choe">Hyeryun Choe</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Pediatrics, Children's Hospital, Harvard Medical School</s1>
<s2>Boston, MA</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Farzan, Michael" sort="Farzan, Michael" uniqKey="Farzan M" first="Michael" last="Farzan">Michael Farzan</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology and Molecular Genetics, Harvard Medical School, New England Primate Research Center</s1>
<s2>Southborough, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">07-0427335</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 07-0427335 INIST</idno>
<idno type="RBID">Pascal:07-0427335</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000351</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000638</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Severe acute respiratory syndrome coronavirus entry as a target of antiviral therapies</title>
<author><name sortKey="Kuhn, Jens H" sort="Kuhn, Jens H" uniqKey="Kuhn J" first="Jens H." last="Kuhn">Jens H. Kuhn</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology and Molecular Genetics, Harvard Medical School, New England Primate Research Center</s1>
<s2>Southborough, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Biology, Chemistry, Pharmacy, Freie Universität Berlin</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Wenhui Li" sort="Wenhui Li" uniqKey="Wenhui Li" last="Wenhui Li">WENHUI LI</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology and Molecular Genetics, Harvard Medical School, New England Primate Research Center</s1>
<s2>Southborough, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Radoshitzky, Sheli R" sort="Radoshitzky, Sheli R" uniqKey="Radoshitzky S" first="Sheli R." last="Radoshitzky">Sheli R. Radoshitzky</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology and Molecular Genetics, Harvard Medical School, New England Primate Research Center</s1>
<s2>Southborough, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Choe, Hyeryun" sort="Choe, Hyeryun" uniqKey="Choe H" first="Hyeryun" last="Choe">Hyeryun Choe</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Pediatrics, Children's Hospital, Harvard Medical School</s1>
<s2>Boston, MA</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Farzan, Michael" sort="Farzan, Michael" uniqKey="Farzan M" first="Michael" last="Farzan">Michael Farzan</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology and Molecular Genetics, Harvard Medical School, New England Primate Research Center</s1>
<s2>Southborough, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Antiviral therapy : (London)</title>
<title level="j" type="abbreviated">Antivir. ther. : (Lond.)</title>
<idno type="ISSN">1359-6535</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Antiviral therapy : (London)</title>
<title level="j" type="abbreviated">Antivir. ther. : (Lond.)</title>
<idno type="ISSN">1359-6535</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral</term>
<term>Coronavirus</term>
<term>Severe acute respiratory syndrome</term>
<term>Targeted therapy</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term>
<term>Coronavirus</term>
<term>Traitement</term>
<term>Antiviral</term>
<term>Thérapeutique ciblée</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The identification in 2003 of a coronavirus as the aetiological agent of severe acute respiratory syndrome (SARS) intensified efforts to understand the biology of coronaviruses in general and SARS coronavirus (SARS-CoV) in particular. Rapid progress was made in describing the SARS-CoV genome, evolution and lifecycle. Identification of angiotensin-converting enzyme 2 (ACE2) as an obligate cellular receptor for SARS-CoV contributed to understanding of the SARS-CoV entry process, and helped to characterize two targets of antiviral therapeutics: the SARS-CoV spike protein and ACE2. Here we describe the role of these proteins in SARS-CoV replication and potential therapeutic strategies aimed at preventing entry of SARS-CoV into target cells.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1359-6535</s0>
</fA01>
<fA03 i2="1"><s0>Antivir. ther. : (Lond.)</s0>
</fA03>
<fA05><s2>12</s2>
</fA05>
<fA06><s2>4</s2>
<s3>p. b</s3>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Severe acute respiratory syndrome coronavirus entry as a target of antiviral therapies</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>Spotlight on respiratory viruses</s1>
</fA09>
<fA11 i1="01" i2="1"><s1>KUHN (Jens H.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>WENHUI LI</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>RADOSHITZKY (Sheli R.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>CHOE (Hyeryun)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>FARZAN (Michael)</s1>
</fA11>
<fA12 i1="01" i2="1"><s1>DE JONG (Menno D.)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="02" i2="1"><s1>HAYDEN (Frederick G.)</s1>
<s9>ed.</s9>
</fA12>
<fA14 i1="01"><s1>Department of Microbiology and Molecular Genetics, Harvard Medical School, New England Primate Research Center</s1>
<s2>Southborough, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Biology, Chemistry, Pharmacy, Freie Universität Berlin</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Pediatrics, Children's Hospital, Harvard Medical School</s1>
<s2>Boston, MA</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA15 i1="01"><s1>Oxford University Clinical Research Unit, Hospital for Tropical Diseases</s1>
<s2>Ho Chi Minh City</s2>
<s3>VNM</s3>
<sZ>1 aut.</sZ>
</fA15>
<fA15 i1="02"><s1>University of Virginia School of Medicine</s1>
<s2>Charlotesville, VA</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA15>
<fA15 i1="03"><s1>Global Influenza Program, World Health Organization</s1>
<s2>Geneva</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
</fA15>
<fA20><s1>639-650</s1>
</fA20>
<fA21><s1>2007</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>27047</s2>
<s5>354000161541800060</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2007 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>163 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>07-0427335</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Antiviral therapy : (London)</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The identification in 2003 of a coronavirus as the aetiological agent of severe acute respiratory syndrome (SARS) intensified efforts to understand the biology of coronaviruses in general and SARS coronavirus (SARS-CoV) in particular. Rapid progress was made in describing the SARS-CoV genome, evolution and lifecycle. Identification of angiotensin-converting enzyme 2 (ACE2) as an obligate cellular receptor for SARS-CoV contributed to understanding of the SARS-CoV entry process, and helped to characterize two targets of antiviral therapeutics: the SARS-CoV spike protein and ACE2. Here we describe the role of these proteins in SARS-CoV replication and potential therapeutic strategies aimed at preventing entry of SARS-CoV into target cells.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02S05</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B05C02C</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Traitement</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Treatment</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Antiviral</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Antiviral</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Antiviral</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Thérapeutique ciblée</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Targeted therapy</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Terapéutica dirigida</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Appareil respiratoire pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Poumon pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Lung disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Pulmón patología</s0>
<s5>38</s5>
</fC07>
<fN21><s1>281</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000638 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000638 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:07-0427335
   |texte=   Severe acute respiratory syndrome coronavirus entry as a target of antiviral therapies
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Severe acute respiratory syndrome coronavirus entry as a target of antiviral therapies

Severe acute respiratory syndrome coronavirus entry as a target of antiviral therapies

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri